Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12142080 | 0.81 | NOS2 (0.52) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL13085564 | 0.79 | NOS2 (0.45) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL13085570 | 0.79 | NOS2 (0.48) | NOS2SLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL1197763 | 0.76 | MAPT (0.54) | NOS2SLC6A4CYP2D6SLC6A2HTR2C | |
| SCHEMBL12143484 | 0.74 | TRPV4 (0.49) | TRPV4 | |
| Hydrochloric Acid SCHEMBL27743366 | 0.74 | MAPT (0.52) | NOS2SLC6A4CYP2D6SLC6A2HTR2C | |
| SCHEMBL6215963 | 0.74 | MAOB (0.60) | NOS2SLC6A4 | |
| SCHEMBL12142904 | 0.72 | SLC6A4 (0.47) | SLC6A4SCN4A | |
| SCHEMBL2866284 | 0.72 | MAOB (0.45) | NOS2HTR2B | |
| SCHEMBL2866287 | 0.72 | MAOB (0.45) | NOS2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | NOS2 645/4885SLC6A4 2901/4885CYP2D6 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.